Abstract: FR-PO0802
Efficacy and Safety of Rituximab (RTX) Combined with Glucocorticoids (GC) in Patients with Primary Membranous Nephropathy (PMN)
Session Information
- Glomerular Diseases: Practice and New Concepts Shaping Modern Care
October 23, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Zhao, Chen, University of Science and Technology of China, Hefei, Anhui, China
- Feng, Yao Shi, University of Science and Technology of China, Hefei, Anhui, China
- Wei, Hu Zhi, University of Science and Technology of China, Hefei, Anhui, China
- Yan, Wang Yan, University of Science and Technology of China, Hefei, Anhui, China
- Ni, Lijun, University of Science and Technology of China, Hefei, Anhui, China
- Chen, Wei, University of Science and Technology of China, Hefei, Anhui, China
- Ren, Wei, University of Science and Technology of China, Hefei, Anhui, China
- Wang, Ke, University of Science and Technology of China, Hefei, Anhui, China
Group or Team Name
- Department of Nephrology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China.
Background
Whether concomitant GC administration confers additional synergistic benefit with RTX remains uncertain. To compare the clinical efficacy and safety of RTX monotherapy versus the combination of RTX and GC in the treatment of PMN.
Methods
This retrospective, single-center cohort study enrolled 128 patients diagnosed with PMN between January 2021 and November 2024. 51 patients received RTX monotherapy and 77 patients received RTX+GC therapy, who were all followed up for 12 months. Primary outcomes were defined as the complete remission and partial remission. Secondary outcomes included the changes in proteinuria, serum albumin (ALB), serum creatinine (sCr), eGFR and adverse events.
Results
Within follow-up time, the complete remission rates in RTX+GC and RTX groups were 55.84% and 43.14%, and the composite remission rates were 88.31% and 86.27%, respectively, with no significant difference by Kaplan–Meier survival analysis. No significant difference was observed in proteinuria, ALB, sCr and eGFR between the two groups. Compared with RTX group, the RTX+GC group exhibited a significantly higher incidence of adverse events. Moreover, the results of the logistic regression identified RTX+GC as an independent risk factor and eGFR as an independent protective factor for infection.
Conclusion
Compared with RTX monotherapy, RTX+GC therapy did not significantly improve the clinical remission rate of patients with PMN, but was associated with a substantially increased risk of infections.
Cumulative complete remission rate (A, P= 0.221) and composite remission rate (B, P= 0.689) of RTX and RTX+GC groups in the 12 months.
Changes of clinical laboratory indicators during 12 months in the RTX and RTX+GC groups. *: P<0.05.
Funding
- Government Support – Non-U.S.